EPALINGES, Switzerland - Mymetics Corporation, a pioneer in the development of mucosal focused vaccines for human infectious diseases, announced that the company had been selected to present their ground breaking results obtained for their preventative HIV-1 vaccine.

The poster is titled "High Protection of Female Macaques from Repeated Intra-Vaginal Challenges with Low-dose of SHIV(SF162P3) upon Mucosal Vaccination with Gp41 subunits-Virosomes inducing Gp41-specific Mucosal Immune Responses". Results show high mucosal protection against repeated live SHIV vaginal challenges after vaccination with Mymetics' preventative HIV-1 vaccine candidate. The vaccinated group showed no detectable viremia while the placebo group became fully infected.

"We are very pleased to share our results with the scientific community attending to the world leading congress on AIDS vaccines," commented Dr. Sylvain Fleury, Chief Scientific Officer of Mymetics Corp; "The results are very encouraging and we believe Mymetics' approach is opening the door to the development of preventative HIV-1 vaccine through mucosal defense mechanism."